Tampa, Florida 33612

  • Graft vs. Host Disease


To determine whether treatment with ustekinumab will alter the ratio of T Regulatory Cell (Treg)/total cluster of differentiation 4 (CD4)+ cells in peripheral blood at day 30 post-hematopoietic cell transplantation (HCT).

Study summary:

This is a comparative study to assess the biologic and clinical activity of the agent ustekinumab when given in concert with our established regimen of SIR/TAC. Patients will be randomly assigned between the standard regimen of tacrolimus/sirolimus (TAC/SIR + placebo) vs. the investigational regimen of tacrolimus/sirolimus/ustekinumab (TAC/SIR/U) in a 1:1 scheme.


Inclusion Criteria: - Hematologic disorder requiring allogeneic hematopoietic cell transplantation - Adequate vital organ function: - Left ventricular ejection fraction (LVEF) >/= 45% by multigated acquisition (MUGA) scan - FEV1, FVC, and diffusing lung capacity oxygenation (DLCO) >/= 50% of predicted values on pulmonary function tests - Transaminases (AST, ALT) < 3 times upper limit of normal values - Creatinine clearance >/= 50 cc/min. - Performance status: Karnofsky Performance Status Score >/= 60%. Exclusion Criteria: - Active infection not controlled with appropriate antimicrobial therapy - HIV, hepatitis B, or hepatitis C infection - Sorror's co-morbidity factors with total score > 3 - Important modification to co-morbidity index calculation: DLCO will not be included in assessment of pulmonary risk, excepting those with DLCO < 50%, who will merit a score of 3 and thereby be excluded from the trial. - Anti-thymocyte globulin (ATG) as part of the conditioning regimen - Cyclophosphamide as part of the conditioning regimens



Primary Contact:

Principal Investigator
Joseph Pidala, MD, MS
H. Lee Moffitt Cancer Center and Research Institute

Backup Contact:


Location Contact:

Tampa, Florida 33612
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: June 22, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.